Skip to content
DataLookout
Menu

NCT07117760

Phase 2 Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Phase changed: Phase 1/2 → Phase 2 Show 5 more changesShow less
    • Enrollment increased: 16 → 24 participants
    • Eligibility criteria expanded, about 26 words
    • Study completion moved earlier from Dec 31, 2029 to Dec 31, 2028
    • Study description expanded, about 2 words
    • Study title expanded, about 1 word
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 20 to confirmed 16
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Prostate-specific antigen 50 (PSA50) response
Timeframe: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
Number of participants with Treatment Emergent Adverse Events
Timeframe: From enrollment till 30 days safety follow-up, assessed up to 50 months (estimated final OS analysis)

Secondary (2)

Progression Free Survival (PFS)
Overall Survival (OS)

Arms and interventions

225Ac-LNC1011Experimental

Participant will receive 3.7 MBq (+/- 10%) 225Ac-LNC1011, once every 8-10 weeks for a planned 4 cycles

Drugs: 225Ac-LNC1011, 68Ga-PSMA-11

Sites

1 site in 1 country

  • Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical UniversityFuzhou, Fujian, China